{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:46:08Z","timestamp":1789994768560,"version":"4.0.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T00:00:00Z","timestamp":1554336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40262-019-00756-2","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T07:18:22Z","timestamp":1554362302000},"page":"1193-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects"],"prefix":"10.1007","volume":"58","author":[{"given":"Tine A.","family":"B\u00e6kdal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanett","family":"Borregaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cilie W.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette","family":"Thomsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,4]]},"reference":[{"key":"756_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1185\/03007990903421994","volume":"26","author":"CE Cooke","year":"2010","unstructured":"Cooke CE, Lee HY, Tong YP, et al. Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization. Curr Med Res Opin. 2010;26:231\u20138.","journal-title":"Curr Med Res Opin"},{"key":"756_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"756_CR3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"756_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"467","key":"756_CR5","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, B\u00e6kdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.","journal-title":"Sci Transl Med"},{"issue":"Suppl. 1","key":"756_CR6","first-page":"1180-P","volume":"66","author":"A Connor","year":"2017","unstructured":"Connor A, Borregaard J, Buckley ST, et al. Site of absorption of an oral formulation of semaglutide. Diabetes. 2017;66(Suppl. 1):1180-P.","journal-title":"Diabetes"},{"key":"756_CR7","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M Davies","year":"2017","unstructured":"Davies M, Pieber TR, Artoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial. JAMA. 2017;318:1460\u201370.","journal-title":"JAMA"},{"key":"756_CR8","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/A:1016212804288","volume":"12","author":"GL Amidon","year":"1995","unstructured":"Amidon GL, Lennern\u00e4s H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413\u201320.","journal-title":"Pharm Res"},{"key":"756_CR9","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.1021\/acs.molpharmaceut.5b00278","volume":"12","author":"M Malm-Erjefalt","year":"2015","unstructured":"Malm-Erjefalt M, Ekblom M, Vouis J, et al. Effect on the gastrointestinal absorption of drugs from different classes in the biopharmaceutics classification system, when treating with liraglutide. Mol Pharm. 2015;12:4166\u201373.","journal-title":"Mol Pharm"},{"key":"756_CR10","unstructured":"Lisinopril 20\u00a0mg tablets. Summary of product characteristics. \nhttps:\/\/www.medicines.org.uk\/emc\/medicine\/24003\n\n. Accessed 30 Oct 2018."},{"key":"756_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","volume":"58","author":"M Lindenberg","year":"2004","unstructured":"Lindenberg M, Kopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm. 2004;58:265\u201378.","journal-title":"Eur J Pharm Biopharm"},{"key":"756_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0091270006291622","volume":"46","author":"D Soon","year":"2006","unstructured":"Soon D, Kothare PA, Linnebjerg H, et al. Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men. J Clin Pharmacol. 2006;46:1179\u201387.","journal-title":"J Clin Pharmacol"},{"key":"756_CR13","unstructured":"Digoxin. Summary of product characteristics. \nhttps:\/\/www.medicines.org.uk\/emc\/medicine\/23944\n\n. Accessed 30 Oct 2018."},{"key":"756_CR14","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1365-2125.2000.00264.x","volume":"50","author":"PH Marathe","year":"2000","unstructured":"Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol. 2000;50:325\u201332.","journal-title":"Br J Clin Pharmacol"},{"key":"756_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/BF00562061","volume":"16","author":"PJ Pentik\u00e4inen","year":"1979","unstructured":"Pentik\u00e4inen PJ, Neuvonen PJ, Penttil\u00e4 A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16:195\u2013202.","journal-title":"Eur J Clin Pharmacol"},{"key":"756_CR16","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1365-2125.1996.tb00017.x","volume":"42","author":"NC Sambol","year":"1996","unstructured":"Sambol NC, Brookes LG, Chiang J, et al. Food intake and dosage level, but not tablet vs solution dosage form, affect the absorption of metformin HCl in man. Br J Clin Pharmacol. 1996;42:510\u20132.","journal-title":"Br J Clin Pharmacol"},{"key":"756_CR17","unstructured":"Food and Drug Administration. Drug interaction studies\u2014study design, data analysis, implications for dosing and labeling recommendations. \nhttps:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm292362.pdf\n\n. Accessed 1 Nov 2018."},{"key":"756_CR18","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf\n\n. Accessed 30 Sept 2018."},{"key":"756_CR19","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s40262-017-0532-6","volume":"56","author":"H Hausner","year":"2017","unstructured":"Hausner H, Derving Karsb\u00f8l J, Holst AG, et al. Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin and digoxin in healthy subjects. Clin Pharmacokinet. 2017;56:1391\u2013401.","journal-title":"Clin Pharmacokinet"},{"key":"756_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0728-4","author":"C Granhall","year":"2018","unstructured":"Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral\u00a0semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet. 2018. \nhttps:\/\/doi.org\/10.1007\/s40262-018-0728-4\n\n(Epub 18 Dec 2018).","journal-title":"Clin Pharmacokinet"},{"key":"756_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81\u201398.","journal-title":"Clin Pharmacokinet"},{"key":"756_CR22","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s40262-018-0649-2","volume":"57","author":"C Granhall","year":"2018","unstructured":"Granhall C, Sondergaard FL, Thomsen M, et al. Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clin Pharmacokinet. 2018;57:1571\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"756_CR23","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1177\/0091270005278806","volume":"45","author":"PA Kothare","year":"2005","unstructured":"Kothare PA, Soon DK, Linnebjerg H, et al. Effect of exenatide on the steady-state pharmacokinetics of digoxin. J Clin Pharmacol. 2005;45:1032\u20137.","journal-title":"J Clin Pharmacol"},{"key":"756_CR24","unstructured":"TRULICITY 1.5\u00a0mg & 0.75\u00a0mg solution for injection. Summary of product characteristics. \nhttps:\/\/www.medicines.org.uk\/emc\/medicine\/29747\n\n. Accessed 30 Aug 2018."},{"key":"756_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"LJ McCreight","year":"2016","unstructured":"McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59:426\u201335.","journal-title":"Diabetologia"},{"key":"756_CR26","unstructured":"Metformin. Summary of product characteristics. \nhttp:\/\/www.medicines.org.uk\/emc\/medicine\/23244\n\n. Accessed 1 Nov 2018."},{"key":"756_CR27","doi-asserted-by":"crossref","unstructured":"Haluzik M, Rosenstock J, Terauchi Y, et al. Effect and safety or oral semaglutide monotherapy in type 2 diabetes: PIONEER 1 trial [oral presentation #38]. Presentation at the European Association for the Study of Diabetes 54th Annual Meeting, 1\u20135 October 2018, Berlin, Germany.","DOI":"10.2337\/db18-2-LB"},{"key":"756_CR28","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00756-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00756-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00756-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T10:48:38Z","timestamp":1587034118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00756-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,4]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["756"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00756-2","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,4]]},"assertion":[{"value":"4 April 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Tine A. B\u00e6kdal, Mette Thomsen, and Thomas W. Anderson are employees of, and own stock, in Novo Nordisk A\/S. Jeanett Borregaard is an employee of Novo Nordisk A\/S. Cilie W. Hansen was an employee of Novo Nordisk A\/S at the time of writing this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"These trials were sponsored by Novo Nordisk A\/S, S\u00f8borg, Denmark.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors participated in the trial design, were involved in data analysis and interpretation, and participated in writing the manuscript, together with medical writing services provided by the sponsor. All authors have approved the submitted manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in these trials.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The datasets generated and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}